Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Incyte Corporation — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.52 (market cap $3.62B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 6.3× iShares MSCI United Kingdom (FTSE)'s market cap, and iShares MSCI United Kingdom (FTSE) is more actively traded (923,896 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and Incyte Corporation for 33 Days on average.
| EWU | INCY | |
|---|---|---|
Market Cap | $3.62B | $22.85B |
Volume | 923,896 | 1,927,029 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $129.93 |
52-Week Low | $41.34 | $83.80 |
Typical Hold Time | 46 Days | 33 Days |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.23, up 0.65% on the day, but faces a bearish technical outlook with 16 sell signals versus 3 buy signals. The stock is testing key support at $46 amid rising UK gilt yields and inflation concerns. Recent UK housing policy announcements have boosted related sectors, but broader European economic pressures and ECB rate hikes create headwinds for the UK-focused ETF.
The outlook remains cautious given technical weakness and macroeconomic pressures from rising interest rates and energy prices. Investment opportunity exists if housing stimulus gains traction, but risks include prolonged inflation and further ECB tightening that could pressure UK equities.
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
